Journal-based CME Course: Administration of AntiSARS-CoV-2 Monoclonal Antibodies After US Food and Drug Administration Deauthorization

Activity ID

9858

Expires

September 2, 2025

Format Type

Journal-based

CME Credit

Fee

$30

CME Provider: JAMA Network Open

Description of CME Course

This cross-sectional study uses time-series data to evaluate the administration of bamlanivimab-etesevimab and casirivimab-imdevimab monoclonal antibody treatments for SARS-CoV-2 infection after the US Food and Drug Administration deauthorized their use in early 2022.

Disclaimers

1. This activity is accredited by the American Medical Association.
2. This activity is free to AMA members.

ABMS Member Board Approvals by Type

ABMS Lifelong Learning CME Activity

Allergy and Immunology

Anesthesiology

Colon and Rectal Surgery

Family Medicine

Medical Genetics and Genomics

Nuclear Medicine

Ophthalmology

Orthopaedic Surgery

Pathology

Physical Medicine and Rehabilitation

Plastic Surgery

Preventive Medicine

Psychiatry and Neurology

Radiology

Thoracic Surgery

Urology

More Information

Commercial Support?

NOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.

General Information on CME Activity

Educational Objectives

To identify the key insights or developments described in this article

Keywords

Health Policy, Coronavirus (COVID-19), Health Care Quality, Regulatory Agencies

Competencies

Medical Knowledge

CME Credit Type

AMA PRA Category 1 Credit

DOI

10.1001/jamanetworkopen.2022.28997